High-Dose Chemotherapy with Autologous Stem Cell Transplant for Breast Cancer: What Have We Learned 25 Years Later?

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 3-5

  Nieto, Yago ^a   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; THY 1 ANTIGEN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL SELECTION; CHEMOTHERAPY; FOLLOW UP; HIGH DOSE CHEMOTHERAPY; HUMAN; META ANALYSIS (TOPIC); METASTATIC BREAST CANCER; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84855450546     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.045     Document Type: Note

References (21)

1. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585-594.
2. Peters W.P., Eder J.P., Henner W.D., et al. High-dose combination chemotherapy with autologous bone marrow support: a phase I trial. J Clin Oncol 1986, 4:646-654.
3. Stemmer S.M., Cagnoni P.J., Shpall E.J., et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996, 14:1463-1472.
4. Nieto Y., Shpall E.J., Bearman S.I., et al. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant 2005, 11:297-306.
5. Teicher B.A., Ara G., Keyes S.R., Herbst R.S., Frei E. Acute invivo resistance in high-dose therapy. Clin Cancer Res 1998, 4:483-491.
6. Elias A.D., Ibrahim J., Richardson P., et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 2002, 8:198-205.
7. Nieto Y., Vredenburgh J.J., Shpall E.J., et al. Pilot study of concurrent administration of trastuzumab with high-dose cyclophosphamide, cisplatin, and BCNU, with autologous hematopoietic progenitor-cell support, in patients with advanced HER2-positive breast cancer. Clin Cancer Res 2004, 10:7136-7143.
8. Shpall E.J., Jones R.B., Bast R.C., et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991, 9:85-93.
9. Shpall E.J., Bast R.C., Joines W.T., et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991, 7:145-151.
10. Shpall E.J., Jones R.B., Bearman S.I., et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994, 12:28-36.
11. Yanovich S., Mitsky P., Cornetta K., et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 2000, 25:1165-1174.
12. Muller A., Kohrt H., Cha S. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2012, 18:125-133.
13. Cooper B.W., Moss T.J., Ross A.A., Ybanez J., Lazarus H.M. Occult tumor contamination of hematopoietic stem-cell does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998, 16:3509-3517.
14. Rizzieri D.A., Vredenburgh J.J., Jones R.B., et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999, 17:3064-3074.
15. Porrata L.F., Ingle J.N., Litzow M.R., et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001, 28:865-871.
16. Bewick M., Conlon M., Parissenti A.M., et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancerundergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 2001, 10:759-768.
17. Rosinski S., McNiece I., Shpall E., Russell P., Nieto Y. Peripheral T-cell levels correlate with outcome of patients undergoing autologous stem cell transplant. Bone Marrow Transplant 2005, 36:425-430.
18. Nieto Y., Shpall E.J., McNiece I.K., et al. Prognostic evaluation of the early lymphocyte recovery in patients with advanced metastatic and non-metastastic breast cancer receiving high-dose chemotherapy with an autologous stem-cell transplant. Clin Cancer Res 2004, 10:5076-5086.
19. Berry D.A., Ueno N.T., Johnson M.M., et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011, 3214-3223.
20. Berry D.A., Ueno N.T., Johnson M.M., et al. High-dose chemotherapy with autologous stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011, 3224-3231.
21. Nieto Y., Nawaz S., Jones R.B., et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002, 20:707-718.